The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 03, 2020

Filed:

Dec. 28, 2018
Applicant:

Yale University, New Haven, CT (US);

Inventors:

Anthony N. Van Den Pol, Branford, CT (US);

Guido Wollmann, Innsbruck, AT;

Assignee:

YALE UNIVERSITY, New Haven, CT (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/766 (2015.01); C12N 7/04 (2006.01); A61K 35/76 (2015.01); A61K 39/205 (2006.01); A61K 39/12 (2006.01); A61K 9/00 (2006.01); A61K 35/12 (2015.01); A61K 45/06 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/766 (2013.01); A61K 9/007 (2013.01); A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 35/12 (2013.01); A61K 39/205 (2013.01); A61K 45/06 (2013.01); C12N 7/00 (2013.01); C12N 7/04 (2013.01); A61K 2039/5152 (2013.01); A61K 2039/5256 (2013.01); C12N 2760/20133 (2013.01); C12N 2760/20222 (2013.01); C12N 2760/20223 (2013.01); C12N 2760/20232 (2013.01); C12N 2760/20234 (2013.01);
Abstract

Methods of treating cancer including administering to a subject with cancer a pharmaceutical composition including an effective amount of a chimeric VSV virus are disclosed. The chimeric viruses are based on a VSV background where the VSV G protein is replaced with one or more heterologous viral glycoproteins. In the most preferred embodiment, the VSV G protein is replaced with the glycoprotein from Lassa virus or a functional fragment thereof. The resulting chimeric virus is an oncolytic virus that is attenuated and safe in the brain, yet still retains sufficient oncolytic activity to infect and destroy cancer cells such glioblastoma, and to generate an immune response against infected cancer cells. Methods of using chimeric viruses as a platform for immunization against other pathogenic microbes are also provided.


Find Patent Forward Citations

Loading…